The GLP-1 Cost Burden on Employers
Employers across the United States face a widening dilemma. Self-funded health systems struggle to balance rising GLP-1 drug costs against the needs of their workforce. These medications — once celebrated as breakthroughs for obesity and diabetes — now place enormous financial strain on benefit plans. Moreover, the pressure shows no signs of easing in the near term.
GLP-1 weight-loss drug coverage has become one of the most debated topics in employer healthcare strategy. Costs remain steep, adherence remains inconsistent, and the return on investment is still uncertain for many plan sponsors.
How Jefferson Health Is Responding
A Diet-First Strategy Saves Millions
Philadelphia-based Jefferson Health is among the latest organizations wrestling with this challenge. The system covers approximately 65,000 employees. Instead of offering immediate GLP-1 coverage, Jefferson launched a comprehensive diet-and-lifestyle program. As a result, the system saved $20 million. Ninety percent of enrolled participants remain actively engaged.
Jefferson CEO Joseph Cacchione, MD, discussed this approach in a recent NBC News interview. He highlighted the savings as proof that structured lifestyle intervention can reduce costs before turning to prescriptions.
Jefferson’s Holistic Philosophy on Weight Management
Jefferson’s official statement further clarifies its position. According to the health system: obesity is a chronic, complex condition requiring comprehensive, compassionate care — not a standalone prescription. Participants work with dedicated clinicians for proper medication selection and dosing. They also receive dietitian support to manage side effects and sustain long-term improvements. This model has delivered strong engagement and adherence rates.
Consequently, Jefferson’s approach blends clinical oversight with behavioral coaching. This model reflects a growing belief among employers that GLP-1s alone cannot solve the obesity challenge.
Health Systems Pulling Back Coverage
A Pattern of Restrictions Across the Country
Jefferson’s pivot fits into a broader national trend. Health systems have cut GLP-1 weight-loss coverage repeatedly over the past few years. Notably, restrictions generally exclude diabetes use cases and apply primarily to obesity treatment.
- Allina Health (Minneapolis) dropped weight-loss GLP-1 coverage for employees as of 2025.
- Fairview Health Services, HealthPartners, and Mayo Clinic (all Minnesota-based) established coverage limits by March 2024. Fairview’s policy targeted savings of at least $10 million.
- RWJBarnabas Health, Ascension, and Hennepin Healthcare discontinued GLP-1 weight-loss coverage entirely.
Beyond cost, employers and systems also cited poor long-term adherence as a key concern. Many enrollees discontinue GLP-1s within the first year, which further reduces the financial case for coverage.
Insurers and State Plans Retreat
ACA Coverage Declining Sharply
The pullback extends well beyond employers. Insurers and state employee health plans are also stepping back from GLP-1 weight-loss coverage in 2026. A December 2025 analysis from healthcare advisory group Leverage|Axiaci identified a notable decline in GLP-1 coverage across ACA payers. Specifically, covered enrollees dropped from 3.6 million in 2024 to 2.8 million in 2026.
Major Insurers and States Cutting Benefits
Several large insurers have tightened access significantly:
- Mass General Brigham Health Plan no longer covers GLP-1s for small employers or individual commercial members as of this year.
- Kaiser Permanente cut base GLP-1 coverage for California commercial and ACA members in early 2025.
- At the state level, Ohio, Idaho, Louisiana, and Massachusetts do not cover weight-loss GLP-1s for state employees.
This wave of coverage cuts signals that payers — both public and private — view the current pricing structure as unsustainable.
Financial Losses Driving Coverage Cuts
BCBS Plans Report Staggering GLP-1 Costs
The financial data behind these decisions is striking. Blue Cross Blue Shield of Michigan reported a $350 million increase in GLP-1 drug costs in 2023 alone. Blue Cross Blue Shield of Massachusetts recorded a $400 million operating loss in 2024, driven largely by GLP-1 spending. Both insurers subsequently pulled back coverage.
These figures underscore a core issue. GLP-1 savings elsewhere in the healthcare system do not yet offset their total drug costs. UnitedHealthcare’s Dan Kueter, CEO of the employer and individual business, said it plainly at the Becker’s 16th Annual Meeting in Chicago: “The incremental use of GLP-1s is not offset by healthcare costs in other areas.”
Oral GLP-1s and Emerging Pricing Relief
Pills Could Change the Cost Equation
Despite the current pressure, relief may be approaching. Oral GLP-1 formulations are entering the market. Both Novo Nordisk and Eli Lilly have received FDA approval for pill-based options. Kueter expects these products to bring down net costs significantly.
He pointed to government-negotiated pricing for Eli Lilly’s Medicare and Medicaid medications — hovering between $100 and $200 per month — as a potential benchmark. Eli Lilly’s Foundayo pill already starts at $149 per month for self-pay patients. However, the federal Medicare weight-loss pilot model built around this pricing was paused by CMS indefinitely.
New Access Pathways From Drugmakers
Subscriptions and Direct-to-Employer Deals
Drugmakers are actively creating alternative access models to reach more patients. In 2026, Novo Nordisk launched a multimonth Wegovy subscription program. Through this initiative, self-pay patients using select telehealth providers can save up to $1,200 annually on injections or $600 on oral formulations.
Additionally, Eli Lilly launched a direct-to-employer platform. This program gives employers a streamlined pathway to offer Zepbound coverage at a list price of $449 per month.
These moves show that manufacturers recognize employer hesitation. Therefore, they are working to reduce friction and lower the entry point for coverage adoption.
What the Future Could Look Like
Long-Term Data and Innovation Point Toward Balance
The long-term picture carries some optimism. Research from professional services firm Aon suggests that sustained GLP-1 use can trim overall medical cost growth over time. Furthermore, oral formulations, competitive pricing, and growing clinical familiarity with these drugs may shift the calculus for employers.
Even so, many benefit plan sponsors still anticipate shifting more healthcare costs to employees in 2026. GLP-1 coverage remains a top concern among employers planning their benefits strategy.
Kueter acknowledged the gap clearly: “As we sit here today, they’re not yet in balance.” However, both industry leaders and researchers believe the equation will eventually shift — likely as oral options become mainstream and prices compress further.
